Prosight Management, LP Cytom X Therapeutics, Inc. Transaction History
Prosight Management, LP
- $281 Million
- Q1 2025
A detailed history of Prosight Management, LP transactions in Cytom X Therapeutics, Inc. stock. As of the latest transaction made, Prosight Management, LP holds 3,930,008 shares of CTMX stock, worth $8.33 Million. This represents 0.9% of its overall portfolio holdings.
Number of Shares
3,930,008
Previous 3,905,000
0.64%
Holding current value
$8.33 Million
Previous $4.02 Million
37.47%
% of portfolio
0.9%
Previous 1.19%
Shares
3 transactions
Others Institutions Holding CTMX
# of Institutions
66Shares Held
44.1MCall Options Held
8.9KPut Options Held
47.9K-
Tang Capital Management LLC San Diego, CA6.72MShares$14.2 Million0.28% of portfolio
-
Bvf Inc San Francisco, CA5.23MShares$11.1 Million0.15% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.12MShares$10.8 Million0.0% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny2.83MShares$5.99 Million0.0% of portfolio
-
Steven Cohen Point72 Asset Management, L.P. | Stamford, Ct2.65MShares$5.62 Million0.0% of portfolio
About CytomX Therapeutics, Inc.
- Ticker CTMX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 65,950,200
- Market Cap $140M
- Description
- CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer. The company's product candidates include CX-2009, an antibody drug conjugates (ADC) against CD166, which is in Phase II clinical...